5. 進行性核上性麻痺 [臨床試験数:82,薬物数:107(DrugBank:36),標的遺伝子数:60,標的パスウェイ数:90

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
42 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04539041January 19, 202125/8/2020Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear PalsyA Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear PalsyProgressive Supranuclear Palsy (PSP)Drug: antisense oligonucleotide;Drug: placeboNovartis PharmaceuticalsNULLNot yet recruiting40 Years75 YearsAll64Phase 1NULL
2NCT04253132January 1, 202117/12/2019Evaluation of Tolfenamic Acid in Individuals With PSP at 12-WeeksA Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Tolfenamic Acid;Drug: PlacebosNeuroTau, Inc.The Cleveland ClinicNot yet recruiting40 Years85 YearsAll24Phase 1/Phase 2United States
3NCT04008355June 22, 202018/6/2019A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSPA Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: AZP2006 oral solution;Drug: Placebo oral solutionAlzProtect SASNULLRecruiting40 Years80 YearsAll36Phase 2France
4NCT03446807January 202020/2/2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot yet recruiting50 YearsN/AAll32Phase 2United States
5NCT04185415December 3, 20192/12/2019A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)Progressive Supranuclear PalsyDrug: bepranemab;Drug: PlaceboUCB Biopharma SRLNULLActive, not recruiting40 YearsN/AAll25Phase 1Belgium;Germany;Spain;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04184063September 16, 201929/7/2019Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA)Progressive Supranuclear Palsy;Multiple System AtrophyDrug: NBMI;Other: PlaceboEmeraMedNULLRecruiting40 Years85 YearsAll16Phase 2Slovenia
7NCT04014387June 2, 201911/4/2019Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)TreatmentDrug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsuleUniversity of California, San FranciscoUS Department of Veterans AffairsRecruiting18 YearsN/AAll60Phase 4United States
8EUCTR2018-000506-34-SI04/02/201909/03/2018EMERA006 - A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA).EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]NBMI Science Ltd.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
20 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noSlovenia
9EUCTR2016-001635-12-ES04/07/201810/05/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
10EUCTR2016-002554-21-GR09/03/201802/01/2018Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 20.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Biogen Idec Research LimitedNULLNot Recruiting Female: yes
Male: yes
396 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noUnited States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2016-001635-12-DE23/11/201720/02/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
12EUCTR2016-001635-12-FR26/10/201717/07/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;France;Canada;Spain;Australia;Germany;Italy
13EUCTR2016-002554-21-DE18/08/201719/04/2017A study of BIIB092 in participants with Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
459Phase 2United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of
14JPRN-JapicCTI-17362701/8/201726/06/2017Study of BMS-986168 in Patients With Progressive Supranuclear Palsy (PASSPORT)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive Supranuclear PalsyIntervention name : BMS-986168
Dosage And administration of the intervention : BMS-986168 intravenous infusion on specified days
Control intervention name : Placebo
Dosage And administration of the control intervention : Placebo intravenous infusion on specified days
Bristol-Myers Squibb K.K.NULL4186BOTH396NULL
15EUCTR2016-002554-21-GB21/07/201710/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
459Phase 2Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2016-002554-21-AT30/06/201720/04/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 21.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092
Biogen Idec Research LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
459Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
17EUCTR2016-002554-21-ES08/06/201724/04/2017A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowingA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 19.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BMS-986168
INN or Proposed INN: BMS986168
Other descriptive name: BMS986168
Bristol-Myers Squibb International CorporationNULLNot RecruitingFemale: yes
Male: yes
396Phase 2United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of
18NCT03068468June 1, 201727/2/2017Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: BIIB092;Drug: PlaceboBiogenNULLTerminated41 Years86 YearsAll490Phase 2United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom
19EUCTR2016-001635-12-IT31/05/201705/02/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA Progressive Supranuclear Palsy
MedDRA version: 20.0Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
ABBVIE DEUTSCHLAND GMBH & CO. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Canada;Australia;Italy
20NCT02985879December 12, 20161/12/2016A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: placebo;Drug: ABBV-8E12AbbVieNULLCompleted40 YearsN/AAll378Phase 2United States;Australia;Canada;France;Germany;Italy;Japan;Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02839642July 26, 201630/6/2016Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyRIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical TrialProgressive Supranuclear Palsy (PSP)Drug: Rivastigmine;Drug: PlaceboAssistance Publique Hopitaux De MarseilleNULLRecruiting41 Years80 YearsAll106Phase 3France
22NCT02460094October 2, 201520/5/2015Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: BIIB092;Drug: PlaceboBiogenNULLCompleted41 Years86 YearsAll48Phase 1United States
23NCT02494024July 201530/6/2015Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyA Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Single dose C2N-8E12;Drug: Single dose placeboC2N DiagnosticsNULLCompleted50 Years85 YearsAll32Phase 1United States
24EUCTR2013-003740-23-ES04/02/201505/12/2013Evaluation of masitinib in the treatment of Progressive Supranuclear PalsyA prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy
MedDRA version: 14.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
AB ScienceNULLNot Recruiting Female: yes
Male: yes
90 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noSpain
25NCT02133846May 20146/5/2014Safety Study of TPI-287 to Treat CBS and PSPA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear PalsyPrimary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2University of California, San FranciscoCBD Solutions;Tau ConsortiumCompleted50 Years85 YearsAll44Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2012-005539-10-DE29/04/201418/12/2013Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Merz Pharmaceuticals GmbHNULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Poland;Germany
27EUCTR2010-019159-23-GB22/12/201008/10/2010A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. Progressive Supranuclear Palsy
MedDRA version: 14.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Allon Therapeutics IncNULLNot Recruiting Female: yes
Male: yes
300 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noFrance;United States;Canada;Australia;Germany;United Kingdom
28EUCTR2010-019159-23-DE08/11/201027/08/2010A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. Progressive Supranuclear Palsy
MedDRA version: 14.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Davunetide
Product Code: AL-108
INN or Proposed INN: Davunetide
Allon Therapeutics IncNULLNot RecruitingFemale: yes
Male: yes
300Phase 2/3France;United States;Canada;Australia;Germany;United Kingdom
29NCT01110720October 201023/4/2010Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Davunetide;Drug: PlaceboAllon TherapeuticsNULLCompleted41 Years85 YearsBoth313Phase 2/Phase 3United States;Australia;Canada;France;Germany;United Kingdom
30EUCTR2008-007520-26-DE24/06/201013/11/2009A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) Progressive Supranuclear Palsy
MedDRA version: 12.0Level: PTClassification code 10036813Term: Progressive supranuclear palsy
Trade Name: Azilect
INN or Proposed INN: Rasagilin
Other descriptive name: RASAGILINE MESILATE
Klinikum der Universität MünchenNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01187888January 201020/8/2010Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)Progressive Supranuclear PalsyDrug: Rasagiline;Drug: Sugar pillProf. Dr. Stefan LorenzlTeva Pharmaceutical Industries;Ludwig-Maximilians - University of MunichTerminated50 Years80 YearsBoth44Phase 3Germany
32NCT01056965January 201021/1/2010Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyA 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted TauopathiesPredicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent AphasiaDrug: davunetide (AL-108, NAP);Drug: Placebo nasal sprayUniversity of California, San FranciscoNULLCompleted40 Years85 YearsAll12Phase 1United States
33NCT01049399December 200913/1/2010Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyA Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: tideglusib;Drug: placeboNoscira SAi3 ResearchCompleted40 Years85 YearsBoth146N/AUnited States;Germany;Spain;United Kingdom
34EUCTR2009-013097-40-ES17/11/200929/07/2009Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderadaEstudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada Parálisis Supranuclear Progresiva leve o moderada
MedDRA version: 9Level: LLTClassification code 10036813Term: Progressive supranuclear palsy
MedDRA version: 9Level: PTClassification code 10036813Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125Spain;Germany;United Kingdom
35EUCTR2009-013097-40-DE06/11/200930/07/2009A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROSA double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0Level: LLTClassification code 10036813Term: Progressive supranuclear palsy
MedDRA version: 12.0Level: PTClassification code 10036813Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125United Kingdom;Spain;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2009-013097-40-GB30/10/200923/07/2009 A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0 Level: LLT Classification code 10036813 Term: Progressive supranuclear palsy
MedDRA version: 12.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy
Noscira S.A.NULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noSpain;Germany;United Kingdom
37NCT00385710November 200610/10/2006Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: valproic acid;Drug: PlaceboNantes University HospitalNULLCompleted45 Years75 YearsBoth28Phase 2France
38NCT00382824September 200628/9/2006Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind StudyProgressive Supranuclear PalsyDietary Supplement: Coenzyme Q10;Other: PlaceboLahey ClinicNULLCompleted30 YearsN/AAll61N/AUnited States
39NCT00328874May 200621/5/2006Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyMono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Coenzyme Q10German Parkinson Study Group (GPS)MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical CenterCompleted40 Years85 YearsAll20Phase 2Germany
40NCT00605930April 200414/1/2008A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Progressive Supranuclear PalsyDietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: PlaceboUniversity of LouisvilleNULLCompletedN/AN/AAll20N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT00532571January 200418/9/2007Effects of Coenzyme Q10 in PSP and CBDEffects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot StudyProgressive Supranuclear Palsy;Neurological DisordersDrug: CoQ10Lahey ClinicNULLCompleted40 YearsN/AAllPhase 2/Phase 3United States
42EUCTR2016-002554-21-FR15/06/2018A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowingA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy Progressive supranuclear palsy
MedDRA version: 20.0Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: BMS-986168
INN or Proposed INN: BMS986168
Other descriptive name: BMS986168
Bristol-Myers Squibb International CorporationNULLNAFemale: yes
Male: yes
396Phase 2United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of